
VIVOTIF is indicated for active oral immunisation against typhoid fever, caused by Salmonella enterica serovar Typhi (S. Typhi), in adults and children aged five years and older.
This vaccine should be used in accordance with official recommendations.
VIVOTIF protects against Salmonella Typhi by mimicking the response to natural infection and stimulating local, cellular and systemic/humoral immunity 2-5
The protective efficacy of VIVOTIF was demonstrated in several large-scale field trials
involving more than 500,000 subjects2


Randomised, placebo-controlled study in an endemic population (Chile)
VIVOTIF is generally well tolerated with a low incidence of adverse events.
Reporting Adverse Events
Adverse events should be reported to Emergent at medicalinformation@ebsi.com
1 capsule taken on Days 1, 3, and 5 may provide up to 3 years of protection against typhoid fever.

Complete vaccination is comprised of the ingestion of three capsules. Optimal immune response may not be achieved unless the entire vaccination schedule is completed.
Revaccination is recommended at three years following the most recent vaccination for all individuals.
Oral administration with 3 capsules over 5 days, each to be taken approximately 1 hour before a meal with cold or lukewarm water
Protection achieved 7-10 days after the last dose for adults and children aged 5 years and over
Refrigerate at 2°C – 8°C
In the case of travel from a non-endemic area to an area where typhoid is endemic, Green Book recommends a booster consisting of the 3 doses of VIVOTIF be administered every 3 years6
VIVOTIF, Salmonella enterica serovar Typhi
Legal category: POM Basic NHS
Storage and Handling:
Cost: £14.17
Order now
For medical enquiries, please contact Medical Information at 0800 088 5449
Free text message
reminders to help patients
stay on course with VIVOTIF.